InforMatrix^®: treatment of rheumatoid arthritis using biologicals

Abstract

This article offers an interactive decision matrix technique (InforMatrix^®), in which a group of experts in rheumatology determine an order of merit within the various biologicals used for rheumatoid arthritis. In this order of merit, six criteria (efficacy, safety, tolerance, ease of use, applicability and costs) are weighed against each other. Data necessary for this weighing process are derived from both literature, as well as clinical practice experience. This article provides an overview of the most relevant clinical trials on the biologicals, as well as a description of the interactive decision matrix technique. Using this interactive matrix technique makes rational consideration of the treatment options for rheumatoid arthritis possible.

Keywords::

• adalimumab
• anakinra
• biological therapies
• etanercept
• infliximab
• InforMatrix^®
• rheumatoid arthritis

Notes

The main InforMatrix criteria are shown in bold. Under each of these are the subcriteria. These InforMatrix criteria are specifically applied to each selected subject. ACR: American College of Rheumatology; HAQ: Health Assessment Questionnaire.